R J Schilder

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 17:2198-207. 1999
  2. ncbi Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Center, Philadelphia, Pennsylvania 19111, USA
    Gynecol Oncol 88:3-8. 2003
  3. ncbi Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Gynecol Oncol 96:103-7. 2005
  4. ncbi Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
    Russell Schilder
    Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911 2412, USA
    Cancer Biother Radiopharm 19:478-81. 2004
  5. ncbi Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 19:1183-94. 2001
  6. ncbi Imatinib mesylate and its potential implications for gynecologic cancers
    Holly Dushkin
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Treat Options Oncol 6:115-20. 2005
  7. ncbi Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 11:5539-48. 2005
  8. ncbi Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects
    Lainie Martin
    From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA
    J Natl Compr Canc Netw 4:955-66. 2006
  9. ncbi Platinum resistance: the role of DNA repair pathways
    Lainie P Martin
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 14:1291-5. 2008
  10. ncbi Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3418-25. 2008

Detail Information

Publications36

  1. ncbi Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 17:2198-207. 1999
    ..To determine the safety and feasibility of delivering multiple cycles of front-line high-dose carboplatin and paclitaxel with hematopoietic peripheral-blood stem cell (PBSC) support...
  2. ncbi Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Center, Philadelphia, Pennsylvania 19111, USA
    Gynecol Oncol 88:3-8. 2003
    ....
  3. ncbi Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Gynecol Oncol 96:103-7. 2005
    ..A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix...
  4. ncbi Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
    Russell Schilder
    Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911 2412, USA
    Cancer Biother Radiopharm 19:478-81. 2004
    ..Toxicities were primarily hematologic and reversible. No additional long-term adverse events have been observed in the follow-up period, and treatment did not preclude subsequent lymphoma therapies...
  5. ncbi Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 19:1183-94. 2001
    ..This approach remains experimental and should be used only in the context of a clinical trial...
  6. ncbi Imatinib mesylate and its potential implications for gynecologic cancers
    Holly Dushkin
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Treat Options Oncol 6:115-20. 2005
    ....
  7. ncbi Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 11:5539-48. 2005
    ....
  8. ncbi Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects
    Lainie Martin
    From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA
    J Natl Compr Canc Netw 4:955-66. 2006
    ..This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment...
  9. ncbi Platinum resistance: the role of DNA repair pathways
    Lainie P Martin
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 14:1291-5. 2008
    ....
  10. ncbi Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3418-25. 2008
    ..The association between the expression of certain markers and clinical outcome was investigated...
  11. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  12. ncbi Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 113:21-7. 2009
    ..Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and if sera-based markers could predict likelihood of response...
  13. ncbi Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support
    Meiyu Shen
    Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:243-50. 2002
    ..In both cases, the models performed well when analyzed in the context of the retrospective and bootstrap analyses. Prospective studies in ovarian cancer patients should be conducted to further tailor the current models...
  14. ncbi Management of recurrent ovarian carcinoma: current status and future directions
    Lainie P Martin
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Oncol 36:112-25. 2009
    ..This review will discuss the role of chemotherapy in recurrent disease, describe the various agents used in this setting, and touch on the role of biologic agents in recurrent epithelial ovarian carcinoma...
  15. ncbi Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis
    Bhavinkumar B Patel
    Division of Basic Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer Genomics Proteomics 5:137-49. 2008
    ..However, there is limited pre-clinical and clinical data on the molecular targets and action of imatinib in ovarian cancer...
  16. ncbi Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma
    Gloria J Morris
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Haematologica 89:1484-91. 2004
    ..Given the non-overlapping toxicities of IFN with those of chemotherapy and antibody-based therapeutics, there may be a role for combination therapies, especially if the biological basis of response to IFN can be elucidated...
  17. ncbi A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gynecol Cancer 19:929-33. 2009
    ....
  18. ncbi A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
    M von Mehren
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Ann Oncol 19:1802-9. 2008
    ..To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies...
  19. ncbi Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy
    W G Negendank
    Department of Nuclear Magnetic Resonance and Medical Spectroscopy, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 55:3286-94. 1995
    ..This information is important for the establishment of appropriate experimental models and provides a basis from which to examine potential clinical uses of 31P magnetic resonance spectroscopy...
  20. ncbi RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 13:4261-70. 2007
    ..We examined whether mTOR inhibition by RAD001 (everolimus) is therapeutically efficacious in the treatment of ovarian cancer as a single agent and in combination with cisplatin...
  21. ncbi Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 22:343-9. 2004
    ..Two patients experienced grade 4 hematologic adverse effects. CONCLUSION: Irofulven administered at the dose and schedule used in this trial was minimally active and resulted in significant toxicity...
  22. ncbi Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Clin Lymphoma 5:S16-21. 2004
    ....
  23. ncbi Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Hossein Borghaei
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Nucl Med 34:4-9. 2004
    ..The ibritumomab tiuxetan regimen is routinely and safely given in an outpatient setting and is completed in 7 to 9 days, and is thus more convenient for patients than chemotherapy...
  24. ncbi Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer
    Robert E Page
    Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cell Oncol 29:289-99. 2007
    ..We sought to determine if there was an association between the expression of the ubiquitously expressed PCs, furin, PACE-4, PC-5 and PC-7, and ovarian tumor progression...
  25. ncbi Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
    ..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...
  26. ncbi Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
    ..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
  27. ncbi Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Ste 850, Chicago, IL 60611, USA
    Blood 103:4429-31. 2004
    ..Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma...
  28. ncbi A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  29. ncbi Chronic myelogenous leukemia
    Ellin Berman
    J Natl Compr Canc Netw 3:732-55. 2005
  30. ncbi Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Clin Lymphoma Myeloma 7:514-7. 2007
    ..Patients weighing > 80 kg with platelet counts of >or= 150 x 10(9)/L receive a lower dose per unit of body weight. We evaluated whether this influences the safety or efficacy of treatment...
  31. ncbi Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:1804-10. 2007
    ..Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined...
  32. ncbi Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
    Stephen M Ansell
    Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:202-4. 2004
    ....
  33. ncbi Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted...
  34. ncbi Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    Leuk Lymphoma 47:629-36. 2006
    ..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients...
  35. ncbi Hodgkin disease/lymphoma
    Richard T Hoppe
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 6:594-622. 2008
  36. ncbi Hodgkin disease/lymphoma. Clinical practice guidelines in oncology
    Richard T Hoppe
    J Natl Compr Canc Netw 4:210-30. 2006